Durvalumab after Chemoradiotherapy for the Treatment of Patients with Stage III Non-Small Cell Lung Cancer: A Lebanese Real-World Study
Authors:
Open Access
- 5 September 2026
- journal article
- Published by Wolters Kluwer Health in Global Advances in Oncology and Hematology
- Vol. 1 (1) , 96-104
Abstract
Background: Based on the PACIFIC trial, durvalumab has been approved since 2018 as consolidation therapy for patients with unresectable stage III non-small cell lung cancer who have not progressed after chemoradiotherapy. Patients seen in everyday practice, however, are more heterogeneous than trial populations. Objectives: To assess the real-world use, effectiveness, and safety of durvalumab in patients with unresectable stage III non-small cell lung cancer in Lebanon. Materials and Methods: This phase IV, retrospective, multicenter study analyzed patient characteristics, progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (AEs). Cox regression was used to assess the impact of age, sex, disease stage, histological subtype, programmed death ligand 1 (PD-L1) expression, type of prior chemoradiotherapy, and interval between chemoradiotherapy completion and durvalumab initiation on PFS. Results: Twenty-five patients were included, most with squamous histology (64%) and stage IIIB disease (92%). Twenty-three patients (92%) received prior concurrent chemoradiotherapy and two (8%) sequential chemoradiotherapy. PD-L1 expression was ≥1% in 40% of patients and <1% in 24%. Six patients (24%) experienced disease progression. Median PFS was 27.0 months (95% CI: 8.32–45.68), with PFS rates of 75.8% at 12 months and 66.3% at 24 months. The OS was 100% at 12 months and 87.5% at 24 months. None of the evaluated clinicopathological factors significantly influenced PFS. Four patients (16%) discontinued durvalumab because of AEs (grade 3 pneumonitis, psoriatic arthritis, grade 3 hepatotoxicity, and allergy). One patient with an adrenal oligometastasis underwent adrenalectomy and successfully resumed durvalumab. Conclusion: Our findings are consistent with those of the PACIFIC trial and other real-world studies, supporting the effectiveness and tolerability of consolidation durvalumab in clinical practice.Keywords
This publication has 22 references indexed in Scilit:
- Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCESMO Open, 2026
- Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2025
- Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trialESMO Open, 2025
- Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-RESMO Open, 2024
- Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 TrialJournal of Thoracic Oncology, 2022
- Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2022
- Real-World Incidence of Pneumonitis in Patients Receiving DurvalumabClinical Lung Cancer, 2022
- Durvalumab: A Review in Extensive-Stage SCLCTargeted Oncology, 2021
- Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trialAnnals of Oncology, 2020
- Anti-PD1/PDL1 induced psoriasisCurrent Problems in Cancer, 2017